Classification of Substance Use Severity and Treatment Outcomes: NIDA CTN Studies

物质使用严重程度和治疗结果的分类：NIDA CTN 研究

• 批准号: 8053547
• 负责人: Li-Tzy Wu
• 金额: $ 37.73万
• 依托单位: DUKE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-01 至 2013-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8053547
• 关键词: Address; Alcohol or Other Drugs use; Algorithms; Area; Beck depression inventory; Biological; Classification; Clinical; Clinical Trials Network; Cultural Characteristics; DSM-V; Data; Data Analyses; Data Files; Data Set; Diagnosis; Diagnostic; Diagnostic and Statistical Manual; Drug Addiction; Drug usage; Equipment and supply inventories; Ethnic Origin; Ethnic group; Foundations; Frequencies; Future; Gender; HIV; Hybrids; Individual; Measurement; Measures; Mediator of activation protein; Mental Depression; Mental Health; Methods; Modeling; National Institute of Drug Abuse; Outcome; Participant; Patient Self-Report; Pattern; Phase; Probability; Quality of life; Race; Randomized; Randomized Clinical Trials; Research; Risk; Risk Behaviors; SF-36; Severities; Sex Characteristics; Solid; Symptoms; Treatment outcome; Work; abstracting; addiction; demographics; design; diagnosis quality; follow-up; health related quality of life; improved; indexing; insight; instrument; meetings; programs; psychological distress; racial and ethnic; racial and ethnic disparities; racial/ethnic difference; response; sex; statistics; theories; treatment trial

DESCRIPTION (provided by applicant): This R21/R33 application is in response to RFA-DA-09-020. It seeks support to address one research area recommended by this RFA "Secondary data analyses of multiple trials in the NIDA Clinical Trials Network (CTN)." By capitalizing on the CTN's wealth of multisite treatment data from multiple trials, we seek to, in the R21 phase (Year 1), 1) identify and create analyzable flat data files from the raw trial data (stacked format), 2) generate study variables and codebooks by programming scoring algorithms for multiple standardized clinical instruments, 3) evaluate the extent of missing data, and 4) examine baseline clinical profiles (substance use and diagnoses, mental health, and quality of life) of trial participants by gender and race/ethnicity in order to guide the R33 phase of work. In the R33 phase (Years 2-4), we plan to evaluate the construct, concurrent, and predictive validity of categorical and dimensional models of substance use diagnoses. The multisite CTN trials present an unparalleled, excellent opportunity to explore and evaluate these clinically and scientifically important issues directly related to treatment outcomes and to the emerging Diagnostic and Statistical Manual Version-IV (DSM-V). Study Aims for R33 are to 1) investigate measurement equivalence of DSM-IV diagnostic questions by gender and race/ethnicity, 2) evaluate the construct and concurrent validity of DSM-IV substance use diagnoses using categorical, dimensional, and integrated hybrid models of diagnostic classification, 3) determine empirically defined drug dependence subtypes (an integrated hybrid model) in predicting subsequent outcomes and to explore the mediator and moderators of the associations, and 4) evaluate empirically-defined comorbid drug dependence subtypes in predicting subsequent outcomes and to explore the mediator and moderators of the associations. Gender/sex differences will be examined in all analyses either through stratified analyses or the inclusions of interaction terms as appropriate. PUBLIC HEALTH RELEVANCE: Randomized clinical trials dominate treatment research today. Findings from the proposed study will make unique contributions to randomized addiction treatment research. They will help inform gender and racial/ethnic differences in the clinical profiles of substance use diagnoses, the quality and clinical utility of self-report diagnostic measures, interpretations of study results within the CTN, and future designs and analyses of addiction treatment trials.

描述（由申请人提供）：此R21/R33应用程序响应RFA-DA-09-020。它寻求支持以解决此RFA建议的一个研究领域“ NIDA临床试验网络（CTN）中多个试验的二级数据分析”。通过从多个试验中利用CTN的大量多站点治疗数据，我们试图在R21阶段（1年），1）从原始试验数据（堆叠格式）中识别并创建可分析的平面数据文件，2）生成研究变量和代码书，通过对多个标准化临床仪器进行编程的剪裁算法，以评估多个标准化的临床仪器，3）评估范围的范围，3）范围范围范围，3）范围和4范围的数据和4个范围（4）范围（4）范围范围和4次和4个范围（4）和4次和4次和4次范围（4）。通过性别和种族/民族的诊断，心理健康和生活质量）为指导R33工作阶段。在R33阶段（2 - 4年）中，我们计划评估物质使用诊断的分类和维度模型的结构，同时和预测有效性。多站点CTN试验提供了一个无与伦比的，绝佳的机会，可以探索和评估与治疗结果直接相关的临床和科学重要问题，以及新兴的诊断和统计手册版本IV（DSM-V）。 Study Aims for R33 are to 1) investigate measurement equivalence of DSM-IV diagnostic questions by gender and race/ethnicity, 2) evaluate the construct and concurrent validity of DSM-IV substance use diagnoses using categorical, dimensional, and integrated hybrid models of diagnostic classification, 3) determine empirically defined drug dependence subtypes (an integrated hybrid model) in predicting subsequent outcomes and探索关联的介体和主持人，以及4）评估经验定义的合并症药物依赖性亚型，以预测随后的结果并探索关联的中介者和主持人。在所有分析分析或相互作用术语的涵义中，将在所有分析中检查性别/性别差异。 公共卫生相关性：随机临床试验今天主导了治疗研究。拟议研究的结果将为随机成瘾治疗研究做出独特的贡献。它们将有助于为物质使用诊断的临床概况，自我报告诊断措施的质量和临床实用性，CTN内的研究结果解释以及成瘾治疗试验的未来设计以及分析。